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NF-E2-related factor 2 (NRF2) regulates the transcription of a battery of metabolic and cytoprotective genes. NRF2 and epidermal
growth factor receptors (EGFRs/HERs) are regulators of cellular proliferation and determinants of cancer initiation and
progression. NRF2 and HERs confer cancers with resistance to several therapeutic agents. Nevertheless, there is limited
understanding of the regulation of HER expression and activation and the link between NRF2 and HER signalling pathways.
We show that NRF2 regulates both basal and inducible expression of HER1, as treatment of ovarian cancer cells (PEO1,
OVCAR3, and SKOV3) with NRF2 activator tBHQ inducing HER1, while inhibition of NRF2 by siRNA knockdown or with
retinoid represses HER1. Furthermore, treatment of cells with tBHQ increased total and phosphorylated NRF2, HER1, and
AKT levels and compromised the cytotoxic eﬀect of lapatinib or erlotinib. Treatment with siRNA or retinoid antagonised the
eﬀect of tBHQ on NRF2 and HER1 levels and enhanced the sensitivity of ovarian cancer cells to lapatinib or erlotinib.
Pharmacological or genetic inhibition of NRF2 and/or treatment with lapatinib or erlotinib elevated cellular ROS and depleted
glutathione. This extends the understanding of NRF2 and its regulation of HER family receptors and opens a strategic target for
improving cancer therapy.
1. Introduction
NF-E2-related factor 2 (NRF2) is a transcription factor that
regulates both basal and oxidative stress-induced transcrip-
tion of many detoxiﬁcation enzymes and cytoprotective
genes, including genes of the metabolic and signal transduc-
tion pathways. NRF2 heterodimerizes with small MAF pro-
teins and then binds to cis-acting antioxidant response
elements (ARE) within the promoters of its target genes to
initiate their transcription. However, under normal basal
conditions, NRF2 is only freely available at a low level in
the cytoplasm with some translocating into the nucleus to
regulate the transcription of certain target genes [1, 2].
The epidermal growth factor receptor (EGFR/HER) kinase
family is a regulator of cellular proliferation, diﬀerentiation,
and survival, as well as being factors leading to cancer initia-
tion, maintenance, and progression. HER receptors become
active when a soluble ligand binds to their ectodomain, lead-
ing to dimerization and subsequent stimulation of the tyro-
sine kinase, resulting in the phosphorylation of tyrosine
residues in the intracellular domain of the receptors. These
phosphotyrosine residues serve as docking sites to recruit a
number of signal adapter proteins containing SH2 and PTB
domains, which link receptor tyrosine kinases (RTKs) to dif-
ferent cellular signalling pathways such as the PI3K/AKT/
mTOR, MAPK, and STAT pathways [3–8]. The HER family
activation kinetics depend signiﬁcantly on their expression
levels which vary across diﬀerent cells and cancers. Likewise,
it is these variations combined with receptor interactions that
drive and confer complexity in the HER receptor family
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behaviour and function. Overexpression of the HER family
has been shown to correlate with poor survival outcomes in
women with advanced staged ovarian cancers, who have
been treated with cytoreductive surgery and combination
therapy [8–13]. HER has also been implicated in ovarian can-
cer metastases and acting in synergy with various molecular
pathways [14–16].
Several studies have implicated NRF2 in promoting
resistance to chemotherapeutic agents, in addition to its con-
tribution to general cytoprotection, metabolic reprograming,
and cell survival [17–21]. Moreover, targeted chemotherapy
involving receptor tyrosine kinase inhibitors (RTKi) against
HER family receptors has generated interest as a potential
strategy to overcome chemoresistance in breast, ovarian,
and other forms of cancers [21–32]. Also, studies have exam-
ined the crosstalk between growth-promoting MAPK and
PI3K pathways and NRF2 antioxidant pathway in numerous
cell systems [1, 33]. However, in the majority of such studies,
the focus was on the regulation of NRF2 activity and its
function by these kinases. While the interaction and complex
formation ofNRF2withHER2 have been reported to enhance
HER signalling [22, 24], we recently demonstrated the tran-
scriptional regulation of HER2 and HER3 by NRF2 [22].
Further, we demonstrated a relationship between NRF2
function, HER2/HER3 signalling, ROS generation, and the
sensitisation of ovarian cancer cells to the killing eﬀects of
the targeted therapeutics, trastuzumab, pertuzumab, or their
combination [22, 24].
In this study, we investigated whether NRF2 regulates the
expression of HER1/EGFR1, as the ﬁndings of such a study
may have implications to the success and/or failure of
HER-targeted therapies involving RTK inhibitors. We now
report on the observed regulation of the HER family recep-
tors by NRF2 to include HER1 (EGFR1). This regulation of
HER1 by NRF2 appeared to modulate the sensitivity of a
panel of ovarian cancer cells to the RTK inhibitors, lapatinib
and erlotinib. This extends our understanding of NRF2 and
its regulation of HER family receptors and opens another
strategic avenue of manipulating NRF2 to enhance the eﬀec-
tiveness of RTK inhibition in order to kill cancer cells and to
overcome resistance to RTKi therapy.
2. Materials and Methods
2.1. Cell Lines, Culture Conditions, and Treatments. Human
ovarian cancer cell lines, PEO1, SKOV3, and OVCAR3, were
maintained in RPMI 1640 media (Gibco Invitrogen) supple-
mented with 10% foetal bovine serum (FBS), 2mM gluta-
mine, 1mM sodium pyruvate, 100μg/mL streptomycin,
and 100U/mL penicillin in an atmosphere of 5% CO2 and
incubated at 37°C. Before experimental treatments, cells were
grown for 24 h in RPMI 1640 media prepared, but replacing
FBS, with 5% double charcoal-stripped FBS (Fisher). Here-
gulin-β1 (HRG, Sigma) was used by preparing 1μmol/L
stock solution made with 5% trehalose and 10% FBS in
phosphate-buﬀered saline (PBS) and diluted to a ﬁnal con-
centration of 1 nmol/L with media during treatments.
Kinase inhibitors targeting HER1 receptor, lapatinib and
erlotinib, were used by directly diluting the drugs in media
to a ﬁnal concentration of 5μM. tert-Butylhydroquinone
(tBHQ; Sigma) and bexarotene (Carbosynth) stock solutions
were made with dimethylsulfoxide (Fisher) and diluted to a
ﬁnal concentration as requiredwithmedia. ForROSdetection,
2′,7′-dichloroﬂuorescin diacetate (DCFDA, Sigma) solution
was prepared with dimethylsulfoxide in amber tubes to a
concentration of 50mM and stored at −20°C in the dark
until used. For the cytotoxicity assay, the CellTiter-Glo®
2.0 assay kit (Promega) was used: stored at −20°C or 4°C
in the dark until use.
2.2. Reactive Oxygen Species (ROS) Detection. The ROS detec-
tion assay was performed with 2′,7′-dichloroﬂuorescin diace-
tate (DCFDA) staining (Sigma). Brieﬂy, cells were seeded in
triplicate at a density of 0.2× 105 cells/well in opaque ﬂat bot-
tom 96-well tissue culture plates in 100μL media without
phenol red and allowed to grow for 18 h. Following transfec-
tion and/or treatments, cells were washed with PBS and
maintained in 100μL of phenol red-free medium and further
incubated for 24h. A 50mM stock solution of DCFDA
was added to each well containing 100μL pre-existing
media to achieve aﬁnal concentration of 25μMand incubated
for 45min at 37°C. Fluorescence signal intensities indicating
ROS levels were recorded by taking readings using a 96-well
ﬂuorescent multiplate reader (MODULUS, Promega) using
excitation and emission spectra of 485nm/535 nm. To nor-
malise the ﬂuorescence signal, cells in the same wells were
stained with Coomassie brilliant blue stain (Sigma) for 1 h
and washed with distilled water and 10% sodium dodecyl
sulphate (SDS) solution was added to release the absorbed
dye for 10min while shaking. The absorbance values at
595 nm were then recorded using a multiplate absorbance
reader (MODULUS, Promega) and the data was used after
normalising the ﬂuorescence values.
2.3. Cloning and Expression Vectors Used in the Study. This
was as described for the cloning of HER2/HER3 promoters
[22, 24]. Brieﬂy, approximately 1.5 kb proximal promoter
region of HER1 was isolated, cloned, and used in the current
study. The HER1 primer sequences used for the construct
were HER1 forward: 5′-GTGCTCGAGGCAAGAAGGGTG
CATTTTGAAG-3′ and HER1 reverse: 5′-GTCAAGCTTGT
CTCTTGGATGGGCCATC-3′. For the cloning HER1 pro-
moter (prHER1), total genomic DNA was isolated from
human cells using DNeasy Blood and Tissue Kit (Qiagen)
and quantiﬁed using AstraGene microvolume spectropho-
tometer (AstraNet). 100 ng of the genomic DNA was used
to amplify the HER1 promoter sequences (MyFi mix,
Bioline) using the relevant primers that incorporated KpnI
and XhoI restriction endonuclease sites 5′ and 3′ ends of
the ampliﬁed promoters. PCR conditions for promoter
ampliﬁcation were initial denaturation of 95°C for 7min
followed by 35 cycles of 95°C for 30 s for denaturation, 50°C
for 30 s for annealing, and 72°C for 90 s for extension and a
ﬁnal extension for 10min at 72°C. The PCR products were
run and extracted from agarose gel (Qiagen), digested using
XhoI andHindIII restriction enzymes (Promega), and ligated
into PGL3 vector (Promega) to create HER1 promoter
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construct (prHER1) driving the expression of luciferase gene
for utilisation in dual luciferase reporter assay (Promega).
The integrity and authenticity of cloned sequences were
determined by sequencing the plasmids using a commercial
sequencing service (http://www.dnaseq.co.uk/). All cloned
constructs were transfected into relevant cell lines using
Lipofectamine 3000 (Life Technologies).
2.4. Protein Extraction and Immunoblotting. For immuno-
blotting, cells were seeded in 60mm tissue culture plates
and grown until 70% conﬂuent. At the time of protein har-
vest, cells were trypsinized (Gibco Invitrogen) and washed
with PBS. Protein lysates were prepared using radioimmune
precipitation assay buﬀer (Pierce Biotech) supplemented
with protease and phosphatase inhibitor cocktail (Pierce
Biotech) and subjected to sonication of 2 cycles for 10 s at
50% pulse. The ﬁnal mixture was shaken gently on ice for
15min, and the proteinous supernatant was obtained follow-
ing centrifugation of the lysates at 14000g for 15min. Proteins
obtained were quantiﬁed by Bradford assay (Sigma-Aldrich)
using bovine serum albumin as a standard, and sample load-
ing buﬀer (NuPAGE LDS, Invitrogen) was added to protein
lysates, heat denatured at 70°C for 20min, and stored
at −20°C until further use. Prepared protein lysates were
loaded into wells of 4–12% gradient SDS-polyacrylamide gels
(NuPAGE Bis-Tris gels, Life Technologies) and subjected to
electrophoresis at 200V for 1-2 h. Following this, proteins
were transferred onto polyvinylidene diﬂuoride membranes
(PVDF, GE Amersham) using the Invitrogen™ iBlot™ 2 Dry
Blotting System, a fast western transfer which lasts for only
7min. Membranes were blocked and then further treated by
incubating with relevant primary antibodies (Table 1) for 2 h
at room temperature or overnight at 4°C, followed by incuba-
tion for 30min at room temperature with appropriate second-
ary (anti-rabbit) antibody. Then, following antibody probes,
the membranes were processed with Pierce ECL 2 Western
blotting substrate (Thermo Scientiﬁc) reagent according to
manufacturer’s protocol. Finally, the membranes and probed
proteins were visualised and the images were camera captured
using Syngene G-BOX Chemi-XX6 Gel Documentation
System (Synoptics, UK). For loading control, immunoblot-
ting of the same lysates was performed and/or reprobed using
β-actin antibody (Abcam Bioscience, UK).
2.5. Luciferase Reporter Assay. For the analysis of promoter
activities and transcriptional regulation of HER1, the 1.5 kb
promoter region of HER1 gene cloned in pGL3 basic vector
(Promega) was transfected into relevant cell lines. Brieﬂy,
cells (PEO1, OVCAR3, and/or SKOV3) were seeded in trip-
licate in 24-well plates at a density of 2× 105 cells per well
and allowed to attach for 18 h. The cells were then transfected
with either 1μg of empty pGL3 basic vector (Promega) or
pGL3 basic vector with cloned fragments of HER1 promoter
driving the expression of luciferase gene, using Lipofecta-
mine 3000 as transfection reagent according to manufac-
turer’s protocol (Life Technologies). Cotransfection was
also performed with 0.2μg of pRL-CMV vector (Promega)
to serve as an internal control of transfection and its eﬃ-
ciency. Following this, cells were allowed to grow for 24 h,
subjected to desired treatments, and lysed, and the protein
lysates were transferred to opaque white bottom 96-well
plates for reading. The dual luciferase activities of ﬁreﬂy
luciferase (from cloned promoters) and Renilla (internal
control) in the harvested lysates were measured sequentially
by following manufacturer’s protocol (Promega) and taking
luminescence readings in a luminometer (MODULUS, Pro-
mega). To determine the transcriptional activity of NRF2-
dependent ARE promoter in PEO1, OVCAR3, and/or
SKOV3 cell lines, basic pGL3 vector (Promega) containing
cloned 8× cis-regulatory ARE promoter elements was trans-
fected into the cell lines grown in 24-well plates and also
subjected to the dual luciferase reporter assay (Promega).
2.6. siRNA Transfection. Small inhibitory RNA (siRNA) was
used to genetically knockdown NRF2 (Hs_NFE2L2_6, Qia-
gen). For siRNA transfection, cells were seeded in triplicate
either in 24-well plates (0.5× 105 cells), in 60mm plates with
cells grown on poly-L lysine-coated coverslips (0.5× 106
cells), or in 96-well plates in triplicate (2× 10 4) and allowed
to grow for 24 h. Following this, cells were cotransfected
using either 20 pmol siRNA and 1μg of diﬀerent PGL3 pro-
moter constructs (24-well plate) or 75 pmol and 100 pmol
siRNA only (60mm plates) or 7 pmol of siRNA (96-well
plate) and incubated for further 24 h. Cells transfected in
24-well plates were further processed for dual luciferase assay
and those in 60mm plates were harvested for immunoblot-
ting or used for imaging analysis while those in 96-well plates
were processed for cytotoxicity assay. In all cases, scrambled
siRNA of appropriate equal quantity to the NRF2-siRNA was
used as a control, while transfection was performed using
Lipofectamine 3000 (Life Technologies) according to manu-
facturer’s protocol.
2.7. Cytotoxicity Assay. The CellTiter-Glo 2.0 assay kit
(Promega) was used to evaluate cell viability, as described
by the manufacturer. Brieﬂy, cells were seeded in a 96-well
plate and allowed to adhere for 18–24 h. Following the dura-
tion of treatments of cells with diﬀerent concentrations of the
various compounds, the plate and its contents were equili-
brated to room temperature for approximately 30min. Then,
a volume of CellTiter-Glo 2.0 reagent equal to the volume of
cell culture medium present in each well was added. The
contents were then mixed for 2min on an orbital shaker to
Table 1: Antibodies used in the study.
Catalogue
Antibody Host Number Company
HER1-EP38Y Rabbit ab52894 Abcam
pHER1 Rabbit ab40815 Abcam
NRF2 Rabbit ab89443 Abcam
pNRF2-EP1809Y Rabbit ab76026 Abcam
pAkt-Ser473 Rabbit ab9271 Cell signalling
HO-1 Rabbit 5853S Cell signalling
HRP-linked
anti-secondary antibody
Rabbit 7074 Cell signalling
β-Actin Rabbit ab1801 Abcam
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induce cell lysis, and the plate was then incubated at room
temperature for 10min to stabilize the luminescent signal.
Finally, the luminescence was recorded using luminometer
(MODULUS, Promega). The luminescent signal is propor-
tional to the amount of ATP in the sample, which indicates
the presence of living and metabolically active cells.
2.8. Measurement of Total Glutathione. The measurement of
total glutathione levels was performed using GSH/GSSG-
Glo™ Assay kit (Promega) according to manufacturer’s
protocols as used by [34], and luminescence was recorded
using luminometer (MODULUS, Promega).
2.9. Statistical Analysis. All statistical analyses were per-
formed using GraphPad Prism software version 6. The
signiﬁcance (value) of diﬀerences of pooled results was
determined by either independent tests or one-way ANOVA
followed by post hoc Tukey’s tests. Signiﬁcance was deﬁned as
(∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, and ∗∗∗∗p < 0 0001).
2.10. Imaging and Analysis. Images were camera captured
using Syngene G-BOX Chemi-XX6 Gel Documentation
System (Synoptics, UK). The images were saved in TIFF ﬁle
format and analysed typically involving the calculation of rel-
ative abundance via integrated optical densitometry analysis
of each protein band. Densitometry was calculated using
ImageJ software and Densitometry 1 Channel plugin (NIH,
USA). All values shown are the protein of interest divided
by the respective β-actin loading control value.
2.11. Identiﬁcation of Putative NRF2 Transcription Sequences.
Putative NRF2 transcription sites in the NRF1 promoter
region were identiﬁed by use of Web-based bioinformatic
analysis software [35].
3. Results
3.1. NRF2 Regulates Both Basal and Inducible Expression of
HER1. We have recently demonstrated that NRF2 regulates
the expression of drug target HER2 and HER3 family recep-
tors [22]. We now sought to examine whether HER1/EGFR1,
another drug target and member of the HER family recep-
tors, is also regulated by NRF2. We used the isolated and
cloned HER1 gene-driven luciferase transcriptional reporter
construct to examine the basal transcriptional expression
of HER1 in a panel of ovarian cancer cell lines (PEO1,
OVCAR3, and SKOV3). There were signiﬁcant high basal
level and diﬀerential expression of HER1 among the cell lines
(Figure 1(a)). We also used similar transcriptional reporter
assays to demonstrate basal and diﬀerential expression
of HER2 receptor which has been shown to be regulated
by NRF2 [22].
To examine whether NRF2 facilitates the inducible
expression of HER1, we repeated the experiment in the pres-
ence of tert-butylhyroxyquinone (BHQ) a classical activator
of NRF2 that acts via AKT [36, 37]. Treatment of cells with
varying and increasing concentrations of tBHQ was found
to increase the expression of HER1 in all three cell lines
(Figure 1(b)). We observed a similar trend and eﬀect of tBHQ
on transcriptional control of gene expression following the
substitution of the reporter assay and the cell lines with stable
clones of MCF7 cells stably expressing 8× cis-elements of
antioxidant response (ARE) to drive the expression of
luciferase gene (AREc32). To re-evaluate and conﬁrm this
observation, cells were treated with either vehicle solvent
(controls) or tBHQ (100μM) for 24 h and total cellular
lysates extracted, blotted, and probed for total NRF2, total
HER1, and pAKT levels. Pretreatment of cells with tBHQ
greatly increased the levels of total NRF2, total HER1, and
pAKT (Figure 1(c)). These results demonstrated that activa-
tion of NRF2 protein caused upregulation of the HER1/
EGFR pathway and activation of total HER1 proteins likely
via the PI3K-AKT pathway [38]. This implies that both anti-
oxidant response and EGFR pathways might be subject to
coregulatory mechanisms and point to the possible role of
NRF2 in mediating the observed transcriptional and transla-
tional upregulation of HER1 receptor expression. A search
for ARE sites in the promoter region of HER1 identiﬁed 5
potential NRF2 binding sites (Figure 2).
3.2. Pharmacological and Genetic Inhibition of NRF2 Causes
Transcriptional and Translational Downregulation of HER1.
To further delineate the role of NRF2 in the regulation of
HER1 receptor expression, we next sought to examine the
expression of HER1 receptor following the antagonism of
NRF2 and its function. Previous studies have used retinoid
or siRNA to pharmacologically or genetically inhibit NRF2
and its function [20, 22, 24, 39]. Thus, we next set up to phar-
macologically or genetically inhibit NRF2 by examining
ovarian cancer cells treated with either retinoid/rexinoid
bexarotene or an NRF2 speciﬁc/targeting siRNA (Figure 3).
Our developed HER1 gene-driven luciferase reporter system
andWestern blot analysis ofHER1 andNRF2 levels were used
to evaluate and delineate the role of NRF2 in the regulation of
HER1 receptor expression. In all three cell lines tested, the
basal transcription levels of HER1 (Figures 3(a) and 3(b))
and the basal levels of total HER1 and total NRF2 and pAKT
(Figures 3(c) and 3(d)) were repressed by both bexarotene
and siRNA. Repressed levels of total HO-1 (Figure 3(d)), a
classical NRF2-regulated cytoprotective gene, was also
observed. A similar trend on transcriptional repression of the
control of gene expression by either bexarotene or siRNA
was also observed following the substitution of the reporter
assay and the cell lines with the stable clones ofMCF7AREc32
cells stably expressing luciferase gene under the control of
8× cis-elements of antioxidant response (ARE) to which
NRF2 is commonly known to bind to as trans-acting
transcription factor.
Further evidence to implicate NRF2 in the regulation of
HER1 expression was obtained when cotreatment of the
ovarian cancer and MCF7 AREc32 cells with tBHQ and
NRF2-siRNA compromised the tBHQ-dependent induction
of either HER1 promoter-driven or ARE-driven luciferase
gene expression in the ovarian cancer cells or in MCF7
AREc32 cells (Figure 4(a)), respectively. This inhibitory eﬀect
of siRNA on the tBHQ-dependent induction of gene expres-
sion (Figure 4a) appeared to be concomitant with decreased
total NRF2 levels in all the cells tested (Figure 4(b)), with
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Figure 1: NRF2 regulates both basal and inducible expression of HER1. (a) Cells exhibit diﬀerent basal expression. Exponentially growing
PEO1, SKOV3, and OVCAR3 cells were transfected with either empty PGL3 basic vector or 1μg PGL3 basic vector with cloned 1.5 kb
fragments of either HER1 (prHER1) or HER2 (prHER3) promoter driving the expression of luciferase gene. Cotransfection with 0.2 μg
pRL-CMV plasmid was performed as an internal transfection control. (b) tBHQ causes transcriptional induction of HER1 and induction
of ARE in a concentration-dependent manner. MCF7-AREc32 which already contains stably cloned 8× cis-antioxidant response elements
(ARE) driving NRF2-dependent expression of luciferase gene was left without any transfection while PEO1, OVCAR3, and SKOV3 cells
were transfected with either empty PGL3 basic vector or 1μg PGL3 basic vector with promoters of HER1-cloned driving HER1 expression
of luciferase gene. Cotransfection with 0.2 μg pRL-CMV plasmid was performed as an internal transfection control. Where required
PEO1, SKOV3, and OVCAR3 cell lines and MCF7-AREc32 stable cell line were treated in quadruplicate with diﬀerent concentrations of
tBHQ as indicated for 24 h. (c) Immunoblot analysis following treatment with tBHQ demonstrated protein induction of HER1 receptor
and also activation of total and with an increase of pAKT. Brieﬂy, exponentially growing cells were either left untreated (UT) or treated
with 100 μM tBHQ for 24 h before being harvested and processed for immunoblotting using relevant antibodies. Bar chart showing total
NRF2, total HER1, and phospho-Akt levels in PEO1, OVCAR3, and SKOV3 cell lines by quantifying immunoblot signal intensities
obtained in the blot image and normalised to the value of UT and expressed as fold change. Data shown in (a) and (b) are the means± S.D.
of triplicates normalised to the value of PGL3 or UT and expressed as fold change with statistical signiﬁcance determined by one-way
ANOVA followed by Tukey’s post hoc test (∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, and ∗∗∗∗p < 0 0001).
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albeit a marginal reduction of total NRF2 in the OVCAR3
cell line.
These ﬁndings collectively strengthen and support the
role of NRF2 in mediating the observed downregulation of
HER1 expression, at both transcriptional and translational
levels, following the treatment of cells with either bexarotene
or siRNA against NRF2.
3.3. Pharmacological or Genetic Inhibition of NRF2 by
Bexarotene or siRNA Elevates Cellular Reactive Oxygen
Species (ROS) andDepletes Glutathione (GSH) Levels.Reactive
oxygen species (ROS) are recognized as secondmessengers in
signal transduction processes and cytoprotection by inﬂuenc-
ing growth, survival, and overall physiological homeostasis
[40, 41]. Also, biochemical strategies to curb ROS include
nonenzymatic and low molecular weight scavengers, such as
glutathione (GSH), and enzymatic antioxidant defense
systems that include GSH biosynthetic enzymes, superoxide
dismutases, catalases, peroxidases, thioredoxins, peroxire-
doxins, and reductases [42, 43] Most importantly, NRF2
drives both the basal and inducible transcription of genes
associated with redox homeostasis and cytoprotection, as
well as other signal transduction pathways [44]. Therefore,
to further examine the relationship between NRF2, ROS,
and the regulation of HER1, we next quantiﬁed total basal
ROS following NRF2 inhibition and knockdown to deter-
mine whether NRF2 depletion caused elevation of ROS.
Loading of cells with 2′,7′-dichloroﬂuorescin diacetate dye,
which is a ﬂuorescent marker of intracellular ROS, following
pretreatment with either bexarotene or siRNA conﬁrmed the
presence and elevation of ROS for 24 and 48 h (Figure 5(a)),
as resultant consequences from both NRF2 inhibition and
siRNA-dependent knockdown (Figure 5(a)).
Following the observed inhibition of NRF2 and increase
in ROS and downregulation of HER1 receptor expression
and levels in ovarian cancer cells after their treatment with
bexarotene and siRNAs, we anticipated that NRF2 knock-
down with siRNA and/or treatment with bexarotene would
cause a depletion of total cellular GSH. To examine this, cells
were either left untreated or treated with bexarotene or
siRNA. Cells stimulated with heregulin (HRG) which is also
reported to induce cellular glutathione were used as a positive
control. After 24 h treatment, HRG induced total cellular
GSH, while both bexarotene and siRNA caused signiﬁcant
depletion of GSH levels in all cells (Figure 5(b)). This study
demonstrates that perturbation in cellular redox status can
inﬂuence the expression of HER1 receptor and may have
implications for HER1 receptor-targeted therapies.
3.4. Chemotherapeutic and Mechanism of Action of RTK
Inhibitors, Lapatinib and Erlotinib, Involves Generation of
ROS and GSH Depletion in Ovarian Cancer. We have
recently demonstrated the connection between NRF2 status
and the modulation of HER2/HER3 family receptors, ROS,
and the mechanism of action and eﬀectiveness of targeted
immunotherapy against ovarian cancer cells [22, 24]. In this
current study, we have also shown similar connectivity of
NRF2 levels, HER1 modulation, and ROS levels in ovarian
cancer cells. These ﬁndings suggested that while retinoids/
rexinoids, like retinoic acid (RA) and bexarotene, inhibit
the NRF2-dependent AR pathway, such treatment might also
elevate cellular ROS levels in the ovarian cancer cell lines.
This led us to hypothesize that the cytotoxic action of RTK
inhibition targeting HER1 receptor (lapatinib and erlotinib)
involves cellular accumulation of ROS concomitant to the
disruption of NRF2 and its function. To address this hypoth-
esis using lapatinib and erlotinib, ﬁrstly total ROS levels in
basal, HRG stimulated, and drug-inhibited states in all three
cell lines were studied. Here as well, HRG which is known to
be a potent ligand for HER receptors was used. The data in
(Figure 6(a)) illustrated that HRG stimulation alone led to a
signiﬁcant increase in ROS levels in all three cell lines as
Transcription factor
Human_IR
Sequence From To Score Strand
NRF2 CACTCCAGGT 1 10 6.292 −
NRF2 AAATTCCTGT 321 330 6.335 −
NRF2 GCAGGAAGCA 591 600 6.091 +
NRF2 AAAGGAACAG 683 692 6.514 +
NRF2 AGCTTCCGCG 1119 1128 7.655 −
NRF2 NRF2
NRF2
NRF2 NRF2
+
Figure 2: Putative NRF2 binding sites in the promoter region of HER1.
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Figure 3: Pharmacological (bexarotene) and genetic inhibition (siRNA) of NRF2 causes transcriptional and translational downregulation of
HER1. Luciferase assay showing transcriptional downregulation of HER1 following NRF2 inhibition by (a) bexarotene or (b) siRNA in PEO1,
OVCAR3, and SKOV3 cell lines. Exponentially growing PEO1, SKOV3, and OVCAR3 excluding MCF7-AREc32 cell lines were transfected
with either empty PGL3 basic vector or 1 μg PGL3 basic vector with cloned HER1 driving the expression of luciferase gene. Cotransfection
with 0.2 μg pRL-CMV plasmid was performed as an internal transfection control as described in the Materials and Methods. At 24 h
posttransfection, cells were (a) either left untreated or treated with 2.5 μM bexarotene. (b) Cells were either transfected with scrambled
siRNA (Sc) or transfected with 20 pmol of NRF2 siRNA (Si) for 24 h. Following treatments, lysates were prepared and luciferase activity
was measured using dual luciferase reporter assay (Promega) in multiplate reader (MODULUS, Promega). (c) Immunoblot analysis
following treatment with bexarotene demonstrated protein downregulation of HER1 receptor and decrease of NRF2, HO-1, and HER1.
Exponentially growing cells were either left untreated (UT) or treated with 2.5 μM bexarotene for 24 h before being harvested and
processed for immunoblotting using relevant antibodies. Bar chart showing total NRF2, HO-1, and total HER1 levels in PEO1, OVCAR3,
and SKOV3 cell lines by quantifying immunoblot signal intensities obtained in (c). (d) Immunoblot analysis following knockdown of
NRF2 demonstrated protein downregulation of both HER1 receptor and decrease of NRF2 and HO-1 in PEO1, OVCAR3, and SKOV3
cell lines. Cells were either transfected with scrambled siRNA (Sc) or transfected with 75 pmol of NRF2 siRNA (Si). After 24 h and 48 h,
cells were harvested and processed for immunoblotting using relevant antibodies. β-Actin of the same blot was used as loading control.
Bar chart shows the levels of relevant proteins by quantifying immunoblot signal intensities obtained and expressed as fold change. Data
shown in (a) and (b) are the means± S.D. of triplicates, normalised to UT or scramble expressed in fold change with statistical signiﬁcance
determined by Student’s t-test (∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001).
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compared to basal levels in unstimulated cells. Moreover, it is
seen that treatment with lapatinib, erlotinib, or their combi-
nation led to ROS generation in all the ovarian cancer cell
line models. ROS elevation was seen at all the time points
(24, 48, 72, and 96 h) tested, with observed elevation of
ROS being diﬀerential in cell- and time-dependent fashion.
For example, there was more signiﬁcant elevation of ROS in
PEO1 cells (at later time points) as compared to OVCAR3
and SKOV3 (Figure 6(a)).
Investigation of the single drug treatment (lapatinib or
erlotinib), in all the cell lines (Figure 6(b)), showed that
lapatinib often generated more ROS than erlotinib, while
their combination failed to generate higher level of ROS
than their singular administration at all the time points
investigated. However, the fact that administration of these
drugs led to generation of ROS (Figure 6(b)) suggests that
ROS could be a contributing factor in cellular cytotoxicity
of lapatinib and erlotinib and implicates the engagement
of AR pathway and inhibition of NRF2 function during
drug action. Thus, we next sought to investigate the status
of the NRF2-ARE antioxidant response of cells following
lapatinib and erlotinib treatments.
3.5. Lapatinib and Erlotinib Disrupt Antioxidant
Transcriptional Response, Suppress NRF2 and HO-1 Protein
Levels, and Elevate Cellular ROS. Bexarotene which on its
own is reported to be an anticancer agent has previously been
shown to inhibit NRF2/ARE in an NRF2-dependent manner
[39]. In order to extend the observations reported in the
previous section, the consequences of NRF2-ARE inhibition
following exposure to the chemotherapeutic drugs were
investigated. Experiments were performed, ﬁrstly in MCF7-
AREc32 cell line and subsequently in the ovarian cancer cell
line models in order to validate and conﬁrm the inhibitory
action of bexarotene and also drugs (lapatinib and erlotinib)
on the NRF2-dependent AR pathway. Exposure to bexaro-
tene alone caused a decrease in total NRF2 levels in OVCA3
and SKOV3 cells (Figure 7a). Interestingly, the levels of
NRF2 in these cell lines were further decreased following
cotreatment with combined chemotherapy (lapatinib and
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Figure 4: Treatment with tBHQ reduces the knockdown eﬀect of siRNA. (a) siRNA-mediated knockdown of NRF2 causes inhibition of its
transcriptional antioxidant program and repression of HER1 level in both constitutive and tBHQ-induced states. MCF7-AREc32 which
already contains stably cloned 8× cis-antioxidant response elements (ARE) driving NRF2-dependent expression of luciferase gene was left
without any transfection while PEO1, OVCAR3, and SKOV3 cells were transfected with either empty PGL3 basic vector or 1μg PGL3
basic vector with promoters of HER1-cloned driving HER1 expression of luciferase gene. Cotransfection with 0.2 μg pRL-CMV plasmid
was performed as an internal transfection control. Where required, cotransfection with either scrambled RNA (Sc) or NRF2 siRNA was
performed using 20 pmol siRNA. At 24 h after transfection, treatment with 100μM tBHQ was performed where indicated for 4 h
following which cells were processed for dual luciferase reporter assay (Promega) to record luciferase activity in multiplate reader
(MODULUS, Promega). (b) Immunoblotting analysis showing repression of NRF2 following NRF2 knockdown by siRNA in PEO1,
OVCAR3, and SKOV3 cell lines. Cells were either transfected with scrambled siRNA (Sc) or transfected with 75 pmol of NRF2 siRNA
(Si). After 48 h, cells were either left untreated or treated with 100 μM tBHQ (T) for 4 h, before being processed for immunoblotting using
relevant antibodies. β-Actin of the same blot was used as loading control. Bar chart shows NRF2 levels by quantifying immunoblot signal
intensities obtained and expressed as fold change. Data in (a) are the means with ±S.D. of triplicates, normalised to scramble with
statistical signiﬁcance determined by one-way ANOVA followed by Tukey’s post hoc test. ∗∗p < 0 01 and ∗∗∗p < 0 001.
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Figure 5: Inhibition and knockdown of NRF2 by bexarotene and siRNA, respectively, elevate the level of ROS and depletion of total
glutathione level. (a) Bexarotene treatment and knockdown of NRF2 by siRNA cause increase in ROS levels. Exponentially growing
cells were seeded in triplicates in opaque ﬂat bottom black-walled 96-well plates for 24 h. Following this, cells were either left
untreated (UT) or treated with 2.5 μM bexarotene or 7 pmol of siRNA (scrambled or targeted) for diﬀerent time points as indicated.
Following incubations, cells were loaded with DCFDA ﬂuorescent stain for 45min and assayed for ROS by measuring ﬂuorescence as
described in Materials and Methods. (b) Bexarotene and siRNA cause depletion of total glutathione. Exponentially growing cells were
seeded in 60mm tissue culture plates for 24 h and either left untreated (UT) or treated with media containing 1 nM heregulin alone
(HRG) or with cotreatment of 2.5μM bexarotene or 100 pmol siRNA for 24 h before being harvested to prepare protein lysates and
processed for glutathione assay as described in Materials and Methods. Data is shown as fold change of bexarotene or siRNA-treated
cells to UT or scrambled siRNA, respectively, with statistical signiﬁcance determined by one-way ANOVA followed by Tukey’s post
hoc test. ∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, and ∗∗∗∗p < 0 0001.
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erlotinib) in PE01 cells. The drug-induced reduction in NRF2
levels suggests that chemotherapy is also targeting NRF2.
Next, using the luciferase ARE reporter MCF7-AREc32 cell
line, it was found that bexarotene treatment signiﬁcantly
inhibited transcriptional activity of NRF2 at all the time
points tested (Figure 7(b)). Bexarotene treatment of MCF7-
AREc32 reporter cell line also elevated ROS levels
(Figure 7(c)). Furthermore, bexarotene enhanced the inhibi-
tory action of the combination of lapatinib and erlotinib on
the AR pathway. Also, bexarotene alone and in combination
with lapatinib and erlotinib reduced the level of HO-1
(Figure 7(a)). These ﬁndings suggested that while bexarotene
inhibits NRF2-dependent AR pathway, such treatment might
also elevate cellular ROS levels in the ovarian cancer cell lines.
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Figure 6: Treatment with lapatinib and erlotinib generates reactive oxygen species (ROS) in ovarian cancer cells. (a) Heregulin treatment
causes persistent elevation of ROS in ovarian cancer cells. Exponentially growing cells were seeded in triplicates in opaque ﬂat bottom
black-walled 96-well plates for 24 h. Following this, cells were either left untreated (UT) or treated with 1 nM heregulin for diﬀerent time
points as indicated. Following incubations, cells were loaded with DCFDA ﬂuorescent stain for 45min and assayed for ROS as described
in Materials and Methods. (b) Lapatinib, erlotinib, and their combination cause ROS generation. Cells were seeded as in (a) and treated
with either 1 nM HRG alone or with cotreatment of 5μM lapatinib (LAP), erlotinib (ERLO), or their combination (COMB) for diﬀerent
time points as indicated, and ROS assay was repeated. For both (a) and (b), the ﬂuorescence reading recorded from each well was
normalised to total cell abundance within the same wells as described in Materials and Methods. Data shown are mean values± S.D of
triplicates, normalised to UT in (a) or HRG in (b) and expressed as fold change. Statistical signiﬁcance was determined between treatment
groups either by independent t-test or one-way ANOVA followed by post hoc Tukey’s test as appropriate and signiﬁcance expressed
according to the scale: (∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, and ∗∗∗∗p < 0 0001).
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Figure 7: Treatment with bexarotene causes inhibition of NRF2-dependent antioxidant response pathway and generates ROS. (A) Western
analysis showing repression of NRF2 and HO-1 levels following bexarotene treatment in PEO1, OVCAR3, and SKOV3 cell lines.
Exponentially growing cells were either left untreated, treated with 2.5 μM bexarotene, or a combination of 2.5 μM bexarotene together
with 5μM of lapatinib and erlotinib for 24 h before being harvested to prepare protein lysates and processed as described in Materials and
Methods. β-Actin was used as loading control. The bars indicate NRF2 and HO-1 levels following quantiﬁcation of immunoblot signal
intensities obtained in (a) and normalised to the value of UT and expressed as fold change. The signal intensities of bands were quantiﬁed
through integrated optical densitometry measurement. (b) Bexarotene treatment causes inhibition of NRF2-dependent transcription.
Exponentially growing AREc32 cell line stably expressing 8× cis-antioxidant response elements driving the expression of luciferase gene in
an NRF2-dependent manner were either left untreated (UT), treated with bexarotene alone, or with bexarotene and combination of
lapatinib and erlotinib for diﬀerent time points as indicated. Following this, cell lysates were prepared and assayed for luciferase activity
(BrightGlo Luciferase System, Promega). (c) Bexarotene treatment causes increase in ROS levels. Exponentially growing AREc32 cell lines
stably expressing 8× cis-antioxidant response elements driving the expression of luciferase gene in an NRF2-dependent manner were
seeded in triplicates in opaque ﬂat bottom black-walled 96-well plates for 24 h. Following this, cells were either left untreated (UT), treated
with bexarotene alone, or with bexarotene and combination of lapatinib or erlotinib for diﬀerent time points as indicated. Following
incubations, cells were loaded with DCFDA ﬂuorescent stain for 45min and assayed for ROS as described in Materials and Methods. Data
are the mean values± S.D of quadruplicates, normalised to untreated (UT) and expressed as fold change with statistical signiﬁcance
determined by one-way ANOVA followed by Tukey’s post hoc test according to the scale ∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001.
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Indeed, treatmentwith bexarotene signiﬁcantly represses total
NRF2 and induced ROS in all three cell lines (Figure 5(a)).
3.6. Activity of Lapatinib, Erlotinib, and Bexarotene Involves
Repression of NRF2-Dependent Transcription and Depletion
of Total Glutathione. Based on the additional decreased levels
of NRF2 observed in the MCF7-AREC32 stable cell line fol-
lowing combined lapatinib and erlotinib with bexarotene
(Figure 7(a)), it appeared that single treatment with lapatinib
or erlotinib or combination could also inhibit NRF2/ARE-
dependent transcription. The MCF7-AREc32 cell line as a
luciferase reporter was used. The results (Figure 8(a))
show that with HRG stimulation a potent ligand for
HER receptors only, a signiﬁcant induction of AR pathway
was observed. However, the cotreatment with combination
of lapatinib and erlotinib and with single drug alone dis-
rupted and suppressed the ARE-dependent induction signif-
icantly thereby inhibiting NRF2 function. Combination of
either lapatinib and bexarotene or erlotinib and bexarotene
also disrupted the function of NRF2, and the greatest inhibi-
tion of NRF2/ARE activity was observed when the cells
were treated with a combination of lapatinib, erlotinib,
and bexarotene (Figure 8(a)).
We envisaged these diﬀerent treatments of cells
(Figure 8(a)) to lead to perturbations in cellular levels of total
GSH, as previously some of these treatments have resulted in
elevated ROS (Figures 5(a), 6, and 7(c)) and GSH depletion
(Figure 5(b)) in cells. Thus, to investigate whether NRF2
repression would also lead to depletion of total cellular
GSH, the panel of ovarian cancer cells (PEO1, OVCAR3,
and SKOV3) was treated in the same manner as the AREc32
cells (Figure 8(a)) for 96h. It was found that the 96 h treat-
ment of ovarian cancer cells with HRG elevated total cellular
GSH levels, while combination of HRG with lapatinib, erloti-
nib, or bexarotene signiﬁcantly reduced the GSH levels in all
the cell lines, albeit with most reduction observed in PEO1
(Figure 8(b)). Generally, the combination of lapatinib with
erlotinib, lapatinib with bexarotene, or erlotinib with bexaro-
tene caused more signiﬁcant GSH depletion than singular
treatments. Contrary to our initial expectation, treatment of
cells with treble drug combination (lapatinib, erlotinib, and
bexarotene) did not cause further GSH depletion than the
combination of any two drugs. These results indicated that
NRF2 inhibition, ROS accumulation, and GSH depletion
may be contributing to the unique mechanism of cytotoxicity
of lapatinib or erlotinib and that bexarotene enhances the
mechanism of action and the cytotoxicity of lapatinib and/
or erlotinib. Overall, this provides support and strengthens
the hypothesis that the cellular cytotoxicity of lapatinib
and/or erlotinib involves the engagement of the AR path-
way and the concomitant inhibition of NRF2 function
during drug action.
3.7. NRF2 Inhibition Sensitises EGFR Pathway to HER1
Targeting Agents. The observation that retinoid (bexarotene)
or tBHQ treatment caused downregulation or upregulation
of HER1 at transcriptional and protein levels suggests that
NRF2 may be directly involved in regulating HER receptor
expression and as such might have a role in responses
to targeted chemotherapies involving HER1. The cellular
cytotoxicity of HER targeting lapatinib and/or erlotinib
culminates with the engagement of AR pathway and the
concomitant inhibition of NRF2 function during drug action.
To answer this important question, PEO1, OVCAR3, and
SKOV3 cells either with lapatinib and erlotinib alone or by
cotreatment with retinoid/rexinoid (bexarotene) were inves-
tigated to examine the consequences of NRF2 inhibition on
drug eﬀects and cellular responses. Treatment with lapatinib
alone represses both pNRF2 and pHER1 levels in the cell
lines (Figures 9(a) and 9(b)). There was also similar concom-
itant marked repression of pAKT levels in PEO1 and SKOV
cell lines by either drug and in combination with bexarotene.
These results are consistent with lapatinib or erlotinib inhi-
biting NRF2 activity and repressing HER1/EGFR. Moreover,
cotreatment with an NRF2 inhibitor (bexarotene) can fur-
ther repress the EGFR signalling pathway and might
sensitize the ovarian cancer cells to the killing eﬀects of lapa-
tinib and/or erlotinib. Furthermore, data in Figure 9(c)
appears to lend support to these assertions, as we observed
signiﬁcant increased cytotoxicity of lapatinib or erlotinib
following the pharmacological inhibition of NRF2 with
bexarotene for 24 h in OVCAR3 and SKOV3. We failed to
record any such increased cytotoxicity of lapatinib or erloti-
nib in PEO1 with the addition of bexarotene; however,
PEO1 appeared to be more sensitive to the cytotoxic eﬀects
of lapatinib or erlotinib.
4. Discussion
HER1 is a member of the EGFR kinase family which is a
driver of cellular proliferation, diﬀerentiation, and survival
[45–47]. This investigation has identiﬁed the transcriptional
(Figure 1(b)) and translational (Figure 1(c)) regulatory roles
of NRF2 for HER1 receptor. We ﬁrst demonstrated that
NRF2 activation by tBHQ not only induced the NRF2
dependent antioxidant response (AR) pathway as expected,
but interestingly also increased HER1 protein levels
(Figure 1(c)). tBHQ is widely known as an NRF2 activator
and can upregulate ARE response-driven genes. Several
possible NRF2 binding sites were identiﬁed in the HER1
promoter region (Figure 2). The regulatory role of NRF2
on HER1 expression is supported by our observed higher
basal levels of HER1 protein in PEO1 and SKOV3 then in
OVCAR3 (Figures 1(b) and 3(b)), as PEO1 and SKOV3 have
been shown before [48] to have higher basal levels of NRF2
than in OVCAR3. On the other hand, pharmacological
(bexarotene) and genetic inhibition of NRF2 downregulated
the basal expression (Figures 3(a) and 3(b)) and levels of
HER1 in the cells (Figure 3). Previous studies have shown
the inhibitory nature of siRNA and retinoids on AR element
[20, 22, 49, 50] and we have used similar approaches to
demonstrate that NRF2 regulates HER2 and HER3 [22].
Interestingly, the regulation of HER1 by NRF2 appeared
to involve AKT (Figures 1(c), 3(c), 3(d), 9(a), and 9(b)),
and the HER family receptor heterodimers are known to
be very powerful elicitors of the PI3K/AKT/mTOR pathway
[51, 52]. Furthermore, elements of the receptor-regulated
PI3K and MAPK are known to regulate NRF2 function
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Figure 8: Treatment with lapatinib, erlotinib, and bexarotene causes inhibition of NRF2-dependent transcription and depletion of total
glutathione levels. (a) Single and combination of lapatinib and erlotinib cause inhibition of NRF2-dependent transcription.
Exponentially growing MCF7-AREc32 cell lines stably expressing cis-regulatory antioxidant response elements driving the expression of
luciferase gene in an NRF2-dependent manner were treated with 1 nM HRG alone or with cotreatment of 5 μM lapatinib and erlotinib
either individually or in combination for diﬀerent time points as indicated. Following this, cell lysates were prepared and assayed for
luciferase activity as described in Materials and Methods. Data shown are mean values± S.D of quadruplicates, normalised to untreated
(UT) and expressed as fold change with statistical signiﬁcance determined by one-way ANOVA followed by Tukey’s post hoc test.
Asterisks indicate signiﬁcant diﬀerences between individual groups as indicated and according to the scale ∗p < 0 05, ∗∗p < 0 01, and
∗∗∗p < 0 001. (b) Single and combination of lapatinib and erlotinib cause decrease in glutathione level. Exponentially growing cells were
seeded in 60mm tissue culture plates for 24 h and either left untreated (UT) or treated with media containing 1 nM heregulin alone
(HRG) or with cotreatment of 5μM lapatinib and erlotinib or their combination with 2.5 μM bexarotene (COMB) for 72 h before
being harvested to prepare protein lysates and processed for glutathione assay. Data are mean values± S.D of triplicates and expressed
as fold change to the UT. Statistical signiﬁcance was determined by one-way ANOVA followed by Tukey’s post hoc test according to
the scale ∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, ∗∗∗∗p < 0 0001.
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Figure 9: Continued.
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[52, 53], while several features of RTK signalling are regu-
lated by ROS which are invariably controlled by NRF2
function [37, 54, 55]. Thus, the HER receptor and AR path-
ways do share common substrates, and both pathways are
cytoprotective and prosurvival in nature, in addition to both
being implicated in anticancer drug resistance. Therefore, the
regulation of HER family receptors, in addition to HER2 and
HER3, is currently extended by this report to include HER1
receptor and has implications for the anticancer eﬀectiveness
of receptor tyrosine kinase inhibitors (RTKi) like lapatinib
and erlotinib that target HER1 receptor.
The small molecule cancer drugs lapatinib and erlotinib
have been in clinical use over the last decade [56]. They are
novel oral dual tyrosine kinase inhibitors blocking HER1
and HER2 pathways that present beneﬁcial eﬀects on breast
and lung cancers with positive HER2. They are also recog-
nized as promising therapeutics targeting the increased
EGFR expression in triple-negative breast cancer (TNBC),
speciﬁcally through their use with other chemotherapies
[57–60]. However, the eﬃcacy of these drugs is potentially
reduced due to limited therapeutic eﬃcacy and frequent
emergence of resistance. The resistance to these molecularly
targeted agents can be due to mutation of the target itself,
as in the case of kinase gatekeeper mutations, the activation
of adaptive feedback loops, or alternative oncogenic path-
ways [60–63]. It is interesting that in most cases the resis-
tance mechanism preserves the original overall pathway
addiction, for example, to the RAS-RAF-MEK-ERK or PI3
kinase-AKT kinase signal transduction cascades. However,
the rational design of combinations to overcome such prob-
lems, as well as the issue of clonal heterogeneity, still proves
challenging [56, 64, 65].
The curative activity of retinoids in the treatment of
patients with acute promyelocytic leukaemia harbouring
translocations in the RARα receptor gene established the
validity of the concept of targeting pathogenetic driver
abnormalities with a small molecule in the clinic [56, 64].
Bexarotene is a retinoid/rexinoid reported to be chemopre-
ventive and chemotherapeutic agents [20, 66, 67], which like
retinoic acid (RA) regulates cell proliferation, diﬀerentiation,
and morphogenesis. It inhibits tumorigenesis through sup-
pression of cell growth and stimulation of cellular diﬀerenti-
ation [67, 68]. Bexarotene is an eﬀective oral retinoid therapy
for the treatment of early and advanced-stage cutaneous
T-cell lymphoma (CTCL), especially in patients who have
failed on other therapies [69, 70]. Interestingly, this work has
highlighted the usefulness of bexarotene to inhibit NRF2
function, to produce ROS, to deplete GSH, and to modulate
the expression and levels of HER1 in ovarian cancer cells.
We showed that NRF2 is likely to be involved in regulating
the transcriptional and translational expression of HER1
receptor and as suchmight have a role in responses to targeted
chemotherapies involving HER1. Furthermore, the cellular
cytotoxicity of HER targeting lapatinib and/or erlotinib
appeared to involve the engagement and perturbation of
AKT and AR pathways leading to the inhibition of NRF2
function during drug action in all the cell lines (Figures 9(a)
and 9(b)). There was also similar concomitant marked
repression of pAKT levels by either drug and in combination
with bexarotene. These results demonstrated that lapatinib
or erlotinib inhibits NRF2 activity to repress HER1/EGFR,
and also, bexarotene, an NRF2 inhibitor, can further repress
EGFR signalling pathway to further sensitize and enhance
the killing eﬀects of lapatinib and/or erlotinib against
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Figure 9: NRF2 inhibition with bexarotene sensitises EGFR signalling pathway to HER1 inhibitors (a) lapatinib and (b) erlotinib.
Immunoblot analysis showing bexarotene-dependent repression of EGFR signalling following its combination with lapatinib and erlotinib.
Exponentially growing cells were either left untreated in media containing 1 nM heregulin (UT) or treated with the same media
containing in the presence of 1 nM heregulin with lapatinib (Lap) alone or erlotinib (Erl) alone, each at 5 μM, or with cotreatment of
2.5 μM bexarotene (Lap +Bex) or (Erl + Bex) for 24 h before and processed for immunoblotting using relevant antibodies, and β-actin was
used as loading control. (c) NRF2 knockdown and inhibition increase the chance of cytotoxicity of HER family-targeted agents, lapatinib
and erlotinib in ovarian cancer cells. Exponentially growing cells were seeded in triplicates in 96-well plates for 24 h. Following this, cells
were either left untreated in media containing 1 nM heregulin (H) or treated with same media containing in the presence of 1 nM HRG
with 5 μM each of lapatinib (H+L) or erlotinib (H+E) or treated with combination 5μM lapatinib and 2.5 μM bexarotene (H+L+BEX)
or combination of 5μM erlotinib and 2.5μM bexarotene (H+ E+BEX). Cell number was assessed indirectly by use of the cell titre glo
assay. Data shown are means± S.D. of triplicates, normalised to (H), expressed in fold change with statistical signiﬁcance was calculated
by one-way ANOVA followed by Tukey’s post hoc test according to the scale: (∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, and ∗∗∗∗p < 0 0001).
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OVCAR3 and SKOV3 ovarian cancer cells (Figures 9(c)).
Although lapatinib and/or erlotinib appeared to be more
cytotoxic towards PEO1 than against OVCAR3 and/or
SKOV3 cells, we could not record any increased cytotoxicity
of lapatinib or erlotinib with bexarotene in PEO1. This may
be related to PEO1’s propensity and addiction to very high
levels and greatly nuclear localised NRF2 [48]; however,
PEO1 appeared to be more sensitive to the cytotoxic eﬀects
of lapatinib or erlotinib. These results indicated that NRF2
inhibition, downregulation of HER1 and AKT expression
(in particular pHER1, pAKT, and pNRF2), ROS accumula-
tion, and GSH depletion inform the basis and the unique
mechanism of cytotoxicity of lapatinib or erlotinib and that
bexarotene enhances the mechanism of action and the
cytotoxicity of lapatinib and/or erlotinib.
Overall, this supports and strengthens the hypothesis that
the cellular cytotoxicity of lapatinib and/or erlotinib involves
the engagement of AR pathway and the concomitant inhibi-
tion of NRF2 function during drug action. In addition to this
study, the foregoing hypothesis is also supported by the
reports that pharmacological inhibition of PI3K/mTOR
inhibition is critical for achieving optimal response to lapati-
nib [57, 61, 71, 72]. Furthermore, HER2 requires HIF-1 for
tumour growth and that HIF is a major downstream regula-
tor of HER2 that protects cells from anoikis and metabolic
stress caused by decreased matrix adhesion [73]. Moreover,
hypoxia/HIF1α induces lapatinib resistance in HER2-
positive breast cancer cells via regulation of DUSP2 and
HIF-1 can bypass the lapatinib-treated inhibition of the
ERK pathway via inhibition of the dual-speciﬁcity phospha-
tase 2 (DUSP2). Since it is well known that several genes and
components of the PI3K/AKT/mTOR, MAPK, and HIF-1
pathways, as well as HER receptors, are under NRF2-driven
transcriptional and functional control [22, 74, 75], then, there
is novelty in inhibiting NRF2 function to augment the mech-
anism of action and eﬀectiveness of anticancer and RTK
targeting therapeutics like lapatinib and erlotinib. Moreover,
a combinatorial targeted therapy, lapatinib, and/or erlotinib
plus bexarotene may eﬀectively overcome lapatinib and/or
erlotinib resistance in vivo and could be further tested in
preclinical and clinical trials for ovarian and other cancer
types. Also, the consideration and evaluation of NRF2 as bio-
marker of susceptibility and/or resistance to RTK inhibition is
an attractive and a timely proposal.
5. Conclusion
This study has demonstrated that perturbation in cellular
redox status can inﬂuence the expression of HER1 receptor
and with implication for HER1 receptor-targeted therapies.
These data suggest that NRF2 regulates HER1 and that
combined treatment of bexarotene, the NRF2 inhibitor, with
distinct HER1 inhibitory agents (lapatinib and/or erlotinib)
can augment the potency of HER1 and RTK signalling inhi-
bition. The ﬁndings in this research have opened up a new
potential avenue of improving the eﬀectiveness of lapatinib
and erlotinib when combined with bexarotene for the treat-
ment of ovarian cancer. The present study oﬀered new
insights into a novel molecular mechanism of action and
eﬀectiveness of lapatinib and/or erlotinib and identiﬁed
NRF2 as an important potential target for treatment of
lapatinib/erlotinib-resistant cancers.
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